Posted by Michael Wonder on 13 Sep 2016
Updated SMC guidance on comparator medicines with a patient access scheme
12 September 2016 - The SMC’s guidance to manufacturers about comparator medicines accepted for use on the basis of a confidential Patient Access Scheme is changing.
As a consequence of current interpretation of commercial confidentiality and competition law issues, the SMC can no longer report on cost effectiveness results that take account of a patient access scheme for a comparator medicine in the detailed advice document.
